Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen around 63% from their February 2025 all-time high of A$31.97 to current levels near A$11.86. What makes this selloff puzzling is that the company achieved its preliminary FY 2025 revenue guidance of A$1.2 billion (US$804…

ByUjjwal MaheshwariJanuary 29, 2026

What happened to Botanix (ASX:BOT) and why are investors sweating

From A$0.53 to A$0.118 Botanix Shows How Fast Biotech Narratives Turn Botanix (ASX:BOT) is a clear example of how quickly sentiment can shift in Australian biotech. The share price has been highly volatile, reaching highs of A$0.53 before falling to A$0.118 today, even after the launch of Sofdra. For context, Sofdra is Botanix’s FDA approved treatment…

ByCharlie YouldenJanuary 27, 2026

Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?

Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or biotech stocks are trading well above...but Compumedics is a commercial-stage company expecting nearly that amount of sales for an entire year. What's the story here? What are the Best ASX stocks to invest in right now? Check…

ByNick SundichJanuary 27, 2026

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this week, hovering around the A$0.70 level following news that the company announced another major clinical milestone. Results from its MASTRR study have been published in the Journal of Trauma and Injury, marking the 116th…

ByUjjwal MaheshwariJanuary 24, 2026

Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy

If there was one ASX company brutally honest about the fact that it could not escape an impact from Trump's tariffs, it was Fisher and Paykel (ASX:FPH). Of course, this was not just because of the tariffs themselves but forex movements and the economic environment. FPH shares fell over 15% in just two months from mid-January…

ByNick SundichJanuary 22, 2026

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Anteris Technologies Gains Momentum with Medtronic Partnership Anteris Technologies (ASX: AVR) jumped more than 30% after announcing a deal that could change its future. The Australian heart valve company secured a massive US$290 million funding package. This included US$200 million from the public and a US$90 million direct investment from Medtronic, the world's largest medical…

ByUjjwal MaheshwariJanuary 22, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA. The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Osteopore signs a major China distribution deal, but risks remain Osteopore (ASX: OSX) surged 71 per cent last Friday after announcing an exclusive distribution deal with Majeton Limited valued at above RMB 12 million (approximately A$2.6 million). The agreement covers China, Hong Kong, and Macau. For a company with a market capitalisation of just A$2.4…

ByUjjwal MaheshwariJanuary 19, 2026

Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Proteomics International begins its US sales push as Medicare reimbursement starts At Proteomics International (ASX: PIQ), new CEO David Morris takes the reins today as the Perth-based medical technology company shifts from research and development to commercial execution. This leadership change comes at a critical time, as US Medicare reimbursement of US$390.75 per test went live…

ByUjjwal MaheshwariJanuary 19, 2026

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

External Validation Sends Shares Flying Zelira Therapeutics shares surged as much as 172% intraday, before settling around 73.5 cents, following a major funding announcement that the market clearly interpreted as far more than just another capital raise. The company announced that its HOPE 1 special purpose vehicle had secured approximately US$33 million in committed capital from…

ByCharlie YouldenJanuary 16, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

What happened to Botanix (ASX:BOT) and why are investors sweating

Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Proteomics International (ASX:PIQ) Appoints New CEO as US Sales Push Begins: Is It Time to Buy?

Zelira Therapeutics (ASX:ZLD) A 170% Surge Backed by Smart, Non-Dilutive Funding

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here